ClinicalTrials.gg
RecruitingNCT04932577CHiFTUpdated Jan 24, 2025

Faecal Microbiota Transplantation for Liver Cirrhosis

A Phase 2/3 interventional study of Faecal microbiota transplantation and Placebo in Liver Cirrhosis, sponsored by University of Aarhus. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by University of Aarhus · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Liver Cirrhosis with a site in Denmark — 6 open to participants now, 7 under way, 1 of them phase 3. Liver Cirrhosis · Denmark.

Planned enrollment
5th of 19
220 · median 70
Started
2021
the only one that year
Phase 2/3
Only one
of the 35
Registered
29th of 35
by date
Lead sponsor
7 of 35
University of Aarhus

Among the 35 studies in Liver Cirrhosis with a site in Denmark, this one is the 5th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2021, is the only one in phase 2/3, and was the 29th registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

6 of the 35 studies in Liver Cirrhosis with a site in Denmark are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Liver Cirrhosis with a site in Denmark, or all of them as a file.
02

Study summary

The purpose is to investigate the effect of faecal microbiota transplantation (FMT) on complications, progression, and mortality of patients with liver cirrhosis. Further, the investigators want to examine the impact of FMT on the gut microbiota, gut barrier function, systemic inflammation, and immune function.

Read the detailed description

Patients with liver disease have a disturbed gut microbiota. This is often associated with disease progression and development of complications, so-called episodes of decompensation. In this trial, we will change the microbiota of these patients by transferring a healthy microbiota through faeces from a healthy donor, a procedure known as faecal microbiota transplantation (FMT). We will examine the effect of FMT on the prognosis and disease progression of the patients. Further, we will examine the mechanistic effects of FMT. We will at random divide 220 patients admitted with decompensation of liver cirrhosis evenly into two groups. One group will receive FMT and the other group will receive placebo. After the treatment, we will follow the patients for one year and examine disease progression as well as changes in their gut microbiota, gut barrier, and immune function.

03

Conditions studied

  • Liver Cirrhosis

Keywords

  • Hepatic encephalopathy
  • Ascites
  • Gastrointestinal bleeding
  • Spontaneous bacterial peritonitis
  • Hepatorenal syndrome
  • Alcoholic hepatitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years
  • Liver cirrhosis with ≤ 12
  • Acute decompensation requiring intervention (ascites, gastrointestinal bleeding, infections leading to progressive liver failure, overthepatic encephalopathy, alcoholic hepatitis)

Exclusion criteria

Exclusion Criteria:

  • More than one organ failure defined by CLIF-SOFA score
  • Untreated apart from non-melanoma skin cancer
  • Untreated viral hepatitis
  • Inflammatory bowel disease
  • Celiac disease
  • Clostridioides Difficile infection
  • Pregnancy
  • Unable to participate based on medical judgement
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Faecal microbiota transplantation

    The patients will receive three applications of FMT consisting of 50 g cryopreserved, homogenized faeces from healthy donors. The faecal material will be dispensed into double-coated, acid-resistant enterocapsules or cryobags. Faeces will be screened according to international guidelines.

    Biological: Faecal microbiota transplantation

  • Placebo comparator
    Placebo

    The placebo products is produced from a suspension of glycerol, saline and food colouring and cannot be distinguished from the active FMT products.

    Biological: Placebo

Interventions

  • BiologicalFaecal microbiota transplantation

    All participant will receive three applications of either FMT or placebo and afterwards followed for 1 year.

    Also known as: FMT

  • BiologicalPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Time to death or new episode of acute decompensation requiring intervention in FMT versus placebo-treated patients.

    Using data from the patient journals, we will be able to examine the exact time to event in each of the patients. To compare the two groups, hazard ratios will be calculated.

    Time frame: 1 year

Secondary outcomes

  1. Time to death or new episode of acute decompensation requiring intervention in FMT versus placebo-treated patients at 3 months and 6 months of follow-up.

    Using data from the patient journals, we will be able to examine the exact time to event in each of the patients. To compare the two groups, hazard ratios will be calculated.

    Time frame: 3 months, 6 months

  2. Number of new decompensations and deaths during follow-up in the FMT versus the placebo-treated patients.

    Incidence rates will be compared between the groups.

    Time frame: 1 year

  3. Time to death in FMT versus placebo-treated patients. -treated patients at 3 months and 6 months of follow-up.

    Using data from the patient journals, we will be able to examine the exact time to event in each of the patients. To compare the two groups, hazard ratios will be calculated.

    Time frame: 1 year, 6 months, 3 months

  4. Change in gut microbiota beta-diversity (Bray-Curtis index) during one year in FMT versus placebo-treated patients by shotgun metagenomic sequencing.

    In stool and saliva samples collected before and at 5 time points following the intervention, we will measure the gut microbiota composition.

    Time frame: 1 year, 6 months, 3 months

  5. Change in plasma concentration of gut translocation markers; lipopolysaccharide binding protein, soluble CD14, fatty acid binding protein 1 during one year in FMT versus placebo-treated patients by ELISA.

    In blood samples collected at baseline and at follow-up visits, we will measure these plasma proteins by ELISA.

    Time frame: 1 year, 6 months, 3 months

  6. Change in plasma and stool concentration of pro- and antiinflammatory cytokines; IL-6, IL-1beta, TNF-alpha, IL-8, IL-10 in response to the intervention by luminex.

    In blood and stool samples collected at baseline and at follow-up visits, we will measure these plasma proteins by luminex.

    Time frame: 1 year, 6 months, 3 months

  7. Change in disease severity in FMT- versus placebo-treated patients.

    The disease severity will be measured with Model for Endstage Liver Disease (MELD) (range 6-40). A high score reflects poor prognosis.

    Time frame: 3 months, 6 months, 1 year.

  8. Change in disease severity in FMT- versus placebo-treated patients.

    The disease severity will be measured with Child-Pugh score (range 5-15). A high score reflects poor prognosis.

    Time frame: 3 months, 6 months, 1 year.

  9. Change in disease severity in FMT- versus placebo-treated patients.

    The disease severity will be measured with CliF-C Acute decompensation scores (range 0-18). A high score reflects poor prognosis.

    Time frame: 3 months, 6 months, 1 year.

  10. Change in metabolic liver function in FMT- versus placebo-treated patients.

    The metabolic liver function will be measured by the aminopyrine breath test

    Time frame: 3 months, 6 months, 1 year.

  11. Change in liver stiffness in FMT- versus placebo-treated patients.

    Liver stiffness will be measured by liver elastography.

    Time frame: 3 months, 6 months, 1 year.

  12. Change in the Liver Frailty Index in FMT- versus placebo-treated patients.

    The Liver Frailty index (grip strength, chair stands, and balance testing) will be calculated and the index will be compared between the treatment groups. A higher LFI indicates more frailty.

    Time frame: 3 months, 6 months, 1 year.

  13. Change in body composition in FMT- versus placebo-treated patients.

    Body composition will be measured by bioimpedance.

    Time frame: 3 months, 6 months, 1 year.

  14. Change in cognitive function as measured by continuous reaction time in FMT- versus placebo-treated patients.

    The cognitive function will be measured with continuous reaction time.

    Time frame: 3 months, 6 months, 1 year.

  15. Change in cognitive function in FMT- versus placebo-treated patients.

    The cognitive function will be measured with the portosystemic encephalopathy syndrome test.

    Time frame: 3 months, 6 months, 1 year.

  16. Change in quality adjusted life years (QALY´s) to evalute health care related costs in FMT- versus placebo-treated patients

    By using the quality-of-life questionnaire (EQ-5D-5L) a single index will be calculated and used to calculate QALY's.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2021 (actual). Primary completion is estimated for May 2026, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2021
First posted
Jun 21, 2021
StartActual
Jul 1, 2021
Primary completionEst.
May 31, 2026
CompletionEst.
May 31, 2027
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04932577
Collaborators
Aarhus University Hospital, Aalborg University Hospital, Odense University Hospital, Hvidovre University Hospital, Aalborg University, Esbjerg Hospital - University Hospital of Southern Denmark, Sjælland University Hospital
Responsible party
Sponsor
First posted
Jun 21, 2021
Start date
Jul 1, 2021
Primary completion
May 31, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jan 24, 2025

Study contacts

Karen Louise Thomsen, PhD
Contact
karethom@rm.dk
+4526949260
Sidsel Støy, PhD
Contact
sidsel.stoy@clin.au.dk
+4561664565

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion